Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Transplant International
Erschienen in: Transplant International 12/2005

01.05.2005 | Review Article

Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B

verfasst von: Bruno Roche, Didier Samuel

Erschienen in: Transplant International | Ausgabe 12/2005

Einloggen, um Zugang zu erhalten

Abstract

The outcome of OLT for HBV-related liver disease is dependent on the prevention of allograft re-infection. Over the past decade, major advances have been made in the management of HBV transplant candidates. The advent of long-term hepatitis B immune globulin (HBIG) administration as a prophylaxis against HBV recurrence, and the introduction of new antiviral agents against HBV infection, such as lamivudine (LAM), were a major breakthrough in the management of these patients. Results of OLT for HBV infection are similar to those achieved with other indications. Pre-OLT antiviral treatment such as LAM can suppress HBV replication before OLT and thus decrease the risk of re-infection of the graft. Combination prophylaxis with LAM and HBIG after transplantation highly effectively reduces the rate of HBV re-infection, even in HBV replicative cirrhotic patients. The optimal HBIG protocol in the LAM era is yet to be defined: dosing of HBIG, routes of administration, and possibility of stopping HBIG. Several antiviral drugs have been developed for the management of HBV infection on the graft, so outcome is currently good.
Literatur
1.
Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung J, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus related liver disease. Hepatology 1991; 13:619.CrossRefPubMed
2.
O’Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus re-infection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14:104.PubMed
3.
Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. New Engl J Med 1993; 329:1842.CrossRefPubMed
4.
Shouval D, Samuel D. Hepatitis B immune globulin to prevent HBV graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32:1189.PubMed
5.
Feray C, Zignego AL, Samuel D, et al. Persistent hepatitis B virus infection of mononuclear cells without concomitant liver infection: transplantation model. Transplantation 1990; 49:1155.
6.
Lauchart W, Muller R, Pichlmayr R. Long-term immunoprophylaxis of hepatitis B virus (HBV) re-infection in recipients of human liver allografts. Transplant Proc 1987; 19:4051.PubMed
7.
Samuel D, Bismuth A, Mathieu D, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337:813.CrossRefPubMed
8.
Roche B, Feray C, Gigou M, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology 2003; 38:86.CrossRefPubMed
9.
Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulins. Hepatology 1996; 24:1327.PubMed
10.
Lerut JP, Donataccio M, Ciccarelli O, et al. Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis. J Hepatol 1999; 30:706.
11.
Blumhardt G, Neuhaus WD, Bechstein L, et al. Liver transplantation in HBsAg positive patients. Transplant Proc 1990; 22:1577.
12.
Muller R, Gubernatis G, Farle M, et al. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunisation. J Hepatol 1991; 13:90.
13.
Lemmens HP, Langrehr JM, Blumhardt G, et al. Outcome following orthotopic liver transplantation in HBsAg positive patients using short or long-term immunoprophylaxis. Transplant Proc 1994; 26:3622.PubMed
14.
Devlin J, Smith HM, O’Grady JG, Portmann B, Tan KC, Williams R. Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients. J Hepatol 1994; 21:204.PubMed
15.
Koenig V, Hopf U, Neuhaus P, et al. Long-term follow up of hepatitis B virus infected recipients after orthotopic liver transplantation. Transplantation 1994; 58:553.
16.
McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61:1358.
17.
Gugenheim J, Crafa F, Fabiani P, et al. Récidive du virus de l’hépatite B après transplantation hépatique. Gastroenterol Clin Biol 1992; 16:430.PubMed
18.
Sawyer RG, McGory RW, Gaffey MJ, et al. Improved clinical outcome with liver transplantation for hepatitis B related cirrhosis. Ann Surg 1998; 227:841.CrossRefPubMed
19.
Nymann T, Shokouh-Amiri MH, Vera SR, Riely CA, Alloway RR, Gaber AO. Prevention of hepatitis B recurrence with indefinite hepatitis B immune globulin (HBIG) prophylaxis after liver transplantation. Clin Transplant 1996; 10:663.PubMed
20.
Marcellin P, Samuel D, Areias J, et al. Pretransplant interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. Hepatology 1994; 19:6.CrossRefPubMed
21.
Tchervenkov J, Tector A, Barkun J, et al. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant. Ann Surg 1997; 226:356.CrossRefPubMed
22.
DeMan RA, Marcellin P, Habal F, et al. A randomized placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology 2000; 32:413.CrossRefPubMed
23.
Singh N, Gayowski T, Wannstedt CF, Wagener MM, Marino IR. Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation 1997; 63:1415.
24.
Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28:585.CrossRefPubMed
25.
Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31:207.CrossRefPubMed
26.
Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33:301.CrossRefPubMed
27.
Kapoor D, Guptan RC, Wakil SM, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000; 33:308.CrossRefPubMed
28.
Perrillo RP, Wright T, Rakela J, et al. A multicenter United States–Canadian trial to assess lamivudine monotherapy before and after transplantation for chronic hepatitis B. Hepatology 2001; 33:424.CrossRefPubMed
29.
Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34:411.CrossRefPubMed
30.
Fontana R, Keeffe E, Carey W, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002; 8:433.CrossRefPubMed
31.
Fontana R, Hann H, Perrillo R, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123:719.CrossRefPubMed
32.
Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129.CrossRefPubMed
33.
Schiff E, Lai CL, Neuhaus P, et al. Adefovir dipivoxil for the treatment of chronic hepatitis B in patients pre- and post-liver transplantation with lamivudine-resistant hepatitis B virus. Hepatology 2002; 36:371A.
34.
Stärkel P, Horsmans Y, Geubel A, et al. Favorable outcome of orthotopic liver transplantation in a patient with subacute liver failure due to emergence of a hepatitis B YMDD escape mutant virus. J Hepatol 2001; 35:679.CrossRefPubMed
35.
Saab S, Kim M, Wright T, et al. Successful orthotopic liver transplantation for lamivudine associated YMDD mutant hepatitis B virus. Gastroenterology 2000; 119:1382.PubMed
36.
Rosenau J, Bahr M, Tillmann HL, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation. Possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34:895.CrossRefPubMed
37.
Seehofer D, Rayes N, Naumann U, et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA-positive patients undergoing liver transplantation. Transplantation 2001; 72:1381.
38.
Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348:1212.CrossRefPubMed
39.
Mutimer D, Dusheiko G, Barrett C, et al. Lamivudine without HBIG for prevention of graft reinfection by hepatitis B: long-term follow up. Transplantation 2000; 70:809.
40.
Lo CM, Cheung ST, Lai, et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001; 233:276.CrossRefPubMed
41.
Malkan G, Cattral M, Humar A, et al. Lamivudine for hepatitis B in liver transplantation. Transplantation 2000; 69:1403.
42.
Mutimer D, Pillay D, Shields P, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46:107.CrossRefPubMed
43.
Lo C, Fung J, Lau G, et al. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 2003; 37:36.CrossRefPubMed
44.
Marzano A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34:903.CrossRefPubMed
45.
Yao FY, Osorio RW, Roberts JP, et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999; 5:491.CrossRefPubMed
46.
Yoshida EM, Erb SR, Partovi N, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5:520.CrossRefPubMed
47.
Angus PW, McCaughan GW, Gane EJ, Crawford DHG, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6:429.CrossRefPubMed
48.
McCaughan GW, Spencer J, Koorey D, Bowden S, Bartholomeusz A, Littlejohn M. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precoce mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999; 6:512.CrossRef
49.
Han SH, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2001; 6:741.CrossRef
50.
Roche B, Samuel D, Roque AM, et al. Intravenous anti-HBs Ig combined with oral lamivudine for prophylaxis against HBV recurrence after liver transplantation (abstract). J Hepatol 1999; 30:A80.
51.
Gane EJ, McCaughan G, Crawford D, et al. Combination lamivudine plus low dose intramuscular hepatitis B immunoglobulin prevents recurrent hepatitis B and may eradicate residual graft infection. Hepatology 2002; 36:221A.
52.
Han SH, Martin P, Edelstein M, et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003; 9:182.CrossRefPubMed
53.
Sanchez-Fueyo A, Rimola A, Grande L, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31:496.CrossRefPubMed
54.
Sanchez-Fueyo A, Martinez-Bauer E, Rimola A. Hepatitis B vaccination after liver transplantation. Hepatology 2002; 36:257.CrossRefPubMed
55.
Bienzle U, Gunther M, Neuhaus R, Neuhaus P. Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results. Liver Transpl 2002; 8:562.CrossRefPubMed
56.
Angelico M, Di Paolo D, Trinito M, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002; 35:176.CrossRefPubMed
57.
Dodson SF, De Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000; 6:434.CrossRefPubMed
58.
Naoumov NV, Lopes AR, Burra P, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001; 34:888.CrossRefPubMed
59.
Buti M, Mas A, Prieto M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38:811.CrossRefPubMed
60.
Rizzetto M, Macagno S, Chiaberge E, et al. Liver transplantation in hepatitis delta virus disease. Lancet 1987; II:469.CrossRef
61.
Samuel D, Zignego AL, Reynes M, et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis due to chronic delta hepatitis. Hepatology 1995; 21:333.CrossRefPubMed
62.
Manzarbeitia C, Reich D, Ortiz J, et al. Safe use of liver donors with positive hepatitis B core antibody. Liver Transpl 2002; 8:556.CrossRefPubMed
63.
Prieto M, Gomez MD, Berenguer M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001; 7:51.CrossRefPubMed
64.
Dickson R, Everhart J, Lake JR, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997; 113:1168.
65.
Douglas D, Rakela J, Wright T, Krom R, Wiesner R. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997; 3:105.CrossRefPubMed
66.
Roche B, Samuel D, Gigou M, et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997; 26:517.CrossRefPubMed
67.
Uemoto S, Sugiyama K, Marusawa H, et al. Transmission of hepatitis B virus from core antibody positive donors in living related liver transplants. Transplantation 1998; 65:494.
68.
Dodson S, Bonham C, Geller D, Cacciarelli T, Rakela J, Fung J. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti HBc-positive donors. Transplantation 1999; 68:1058.
69.
Yu AS, Vierling J, Colquhoun S, et al. Transmission of hepatitis B virus infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001; 7:513.CrossRefPubMed
70.
Terrault NA, Combs Holland C, Ferrell L, et al. Interferon alpha for recurrent hepatitis B infection after liver transplantation. Liver Transpl Surg 1996; 2:132.PubMed
71.
Gish RG, Lau JYN, Brooks L, et al. Ganciclovir treatment of hepatitis B virus (HBV) infection in liver transplant patients. Hepatology 1996; 23:1.
72.
Roche B, Samuel D, Gigou M, et al. Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation. J Hepatol 1999; 31:584.CrossRefPubMed
73.
Rayes N, Seehofer D, Hopf U, et al. Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation. Transplantation 2001; 71:96.
74.
Perrillo R, Rakela J, Dienstag J, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29:1581.CrossRefPubMed
75.
Roche B, Samuel D, Roque AM, et al. Lamivudine therapy for HBV infection after liver transplantation (abstract). J Hepatol 1999; 30:78.
76.
Nery JR, Weppler D, Rodriguez M, Ruiz P, Schiff ER, Tzakis AG. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 1998; 65:1615.
77.
Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl 2001; 7:113.CrossRefPubMed
78.
Andreone P, Caraceni P, Grazi GL, et al. Lamivudine treatment for acute hepatitis B after liver transplantation. J Hepatol 1998; 29:985.CrossRefPubMed
79.
Fischer L, Sterneck M, Zöllner B, Rogiers X. Lamivudine improves the prognosis of patients with hepatitis B after liver transplantation. Transplant Proc 2000; 32:2128.CrossRefPubMed
80.
Malkan G, Cattral M, Humar A, et al. Lamivudine for hepatitis B in liver transplantation. Transplantation 2000; 69:1403.
81.
Fontana RJ, Hann HW, Wright T, et al. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001; 6:504.CrossRef
82.
Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27:1711.CrossRefPubMed
83.
Bock CT, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122:264.PubMed
84.
Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129.CrossRefPubMed
85.
Peters MG, Singer G, Howard T, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on Adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999; 68:1912.
86.
Mutimer D, Feraz-Neto BH, Harrison R, et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 2001; 49:860.CrossRefPubMed
87.
Walsh KM, Woodall T, Lamy P, et al. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001; 49:436.CrossRefPubMed
88.
Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292.CrossRefPubMed
89.
Shakil AO, Lilly L, Angus P, Gerken G, Thomas N. Entecavir reduces viral load in liver transplant patients who have failed prophylaxis or treatment for hepatitis B (abstract). Hepatology 2001; 34[Suppl]:619.
90.
Van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002; 36:507.PubMed
91.
Crippin J, Foster B, Carlen S, Borcich A, Bodenheimer H. Retransplantation in hepatitis B—a multicenter experience. Transplantation 1994; 57:823.
92.
Roche B, Samuel D, Feray C, et al. Retransplantation of the liver for recurrent hepatitis B virus infection: the Paul Brousse experience. Liver Transpl Surg 1999; 5:166.CrossRefPubMed
93.
Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35:1528.CrossRefPubMed
Metadaten
Titel
Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B
verfasst von
Bruno Roche
Didier Samuel
Publikationsdatum
01.05.2005
Verlag
Springer-Verlag
Erschienen in
Transplant International / Ausgabe 12/2005
Print ISSN: 0934-0874
Elektronische ISSN: 1432-2277
DOI
https://doi.org/10.1007/s00147-004-0797-1

Weitere Artikel der Ausgabe 12/2005

Transplant International 12/2005 Zur Ausgabe

Acknowledgement

Acknowledgement to Reviewers 2004

Original Article

Arterialisation of the portal vein as a model for the induction of hepatic fibrosis: description of microsurgical models in the rat

Original Article

Strain-specific in vitro cytokine production profiles do not predict rat liver allograft survival

Case report

Successful ablation of atrioventricular accessory pathway after cardiac transplantation

Original Article

Analysis of pig-to-human porcine endogenous retrovirus transmission in a triple-species kidney xenotransplantation model

Original Article

The novel calcineurin inhibitor ISA247: a more potent immunosuppressant than cyclosporine in vitro

Neu im Fachgebiet Chirurgie

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.
Bildnachweise